Abstract: The invention relates to a pharmaceutical composition for normalizing the fibrogenic effect of an agonist which comprises an effective amount of an agonist to stimulate normal collagen synthesis together with an effective amount of an antagonist to reduce the agonist-mediated increase of collagen synthesis and collagen gene expression, together with a pharmaceutically acceptable carrier. The invention also relates to a method of normalizing the fibrogenic effect of an agonist with said composition.